Smith & Nephew SNATS (SNN) Stock Price

Smith & Nephew SNATS Price

NYSE·CLOSED
30.88
​
Market closed

Revenue has compounded at 4.3% per year over the past 19 years to 6.16 B USD. Earnings per share have grown at 3.2% per year over the last 19 years. Smith & Nephew SNATS's net margin stands at 10.1%, broadly stable from 10.1% several years earlier. Analysts set a median price target of 30.93 USD, implying 0.1% above the current price. Of 24 analysts, 9 rate the stock a buy — an overall Hold consensus.

Smith & Nephew SNATS stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS business model & stock analysis

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions about Smith & Nephew SNATS

Analysts currently set an average price target of 30.93 USD for the Smith & Nephew SNATS stock (median: 30.93 USD), implying +0.2 % versus the latest price. The consensus is based on 24 analyst ratings.

24 analysts currently rate the Smith & Nephew SNATS stock: 9 recommend buying, 14 holding and 1 selling. For 2026, analysts expect Smith & Nephew SNATS to generate revenue of 6.47 B USD and earnings per share of 2.13 USD.

Converted at the current exchange rate, the Smith & Nephew SNATS share trades at 27.53 EUR (30.88 USD).

The expected revenue of Smith & Nephew SNATS is 6.47 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Smith & Nephew SNATS is 929.22 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Smith & Nephew SNATS is currently 14.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Smith & Nephew SNATS stock.

The price-to-sales ratio (P/S) of Smith & Nephew SNATS is currently 2.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Smith & Nephew SNATS stock.

The Eulerpool Quality Score for Smith & Nephew SNATS is 5/10.

The ISIN of Smith & Nephew SNATS is US83175M2052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Smith & Nephew SNATS is SNN. The ticker symbol is used to trade Smith & Nephew SNATS shares on the stock exchange.

Fair ValueTerminal
29.64 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
351,625.78 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 16, 1999
ISIN
US83175M2052
Cusip
83175M106
Market capitalization
13.08 B USDLarge Cap
52-Week Range
PEG
3.41
P/E ratio
P/Ee 2026
14.08
P/Ee 2027
12.93
P/Ee 2028
11.56
P/Ee 2029
10.90
P/Ee 2030
10.36
P/S
P/Se
2.08
EV/EBIT
19.96
P/B Ratio
2.47
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.25 %
Last updated Oct 23, 2026, 3:06 PM

Smith & Nephew SNATS Peer Group